grant
Therapeutic vaccine platform to boost immune responses in Tuberculosis
Organization L2 DIAGNOSTICS, LLCLocation NEW HAVEN, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2027
NIHUS FederalResearch GrantFY2025Algorithm DesignAlgorithmic DesignAlgorithmic EngineeringAssayBioassayBiological AssayBusinessesContracting OpportunitiesContractsDevelopmentDrugsEncapsulatedFormulationGoalsHBV diseaseHIV and HBVHIV and hepatitis BHIV-HBVHIV/HBVHIV/hepatitis BHIV/hepatitis B virusHepBHepatitis BImmune responseIn VitroM tbM tuberculosisM tuberculosis antigenM tuberculosis infectionM. tbM. tb infectionM. tuberculosisM. tuberculosis antigenM. tuberculosis infectionM.tb antigenM.tb infectionM.tuberculosis infectionMTB infectionMTB vaccineMedicationMessenger RNAMiceMice MammalsMtb antigenMurineMusMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis antigensMycobacterium tuberculosis infectionPharmaceutical PreparationsRNA vaccineRNA-based vaccineRegimenResearchSBIRSmall Business Innovation ResearchSmall Business Innovation Research GrantTB infectionTB vaccineTuberculosisTuberculosis VaccinesVaccine for TBVaccine for TuberculosisViral Hepatitis Balgorithm engineeringalgorithmic compositionanti-TB vaccineantiretroviral therapyantiretroviral treatmentdesigndesigningdetermine efficacydevelopmentaldisseminated TBdisseminated tuberculosisdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyhep Bhepatitis B virus and human immunodeficiency virushepatitis B virus diseasehost responseimmune system responseimmunogenicityimmunoresponseinfection due to Mycobacterium tuberculosismRNAmRNA vaccinemRNA-based vaccinemtbnew drug classnovelnovel drug classprototypetherapeutic vaccinetreatment vaccinestuberculosis infectiontuberculous spondyloarthropathyvaccine against M. tuberculosisvaccine against Mtbvaccine against Mycobacterium tuberculosisvaccine against TBvaccine against tuberculosisvaccine candidates against tuberculosisvaccine for the treatmentvaccine for treatmentvaccine platform
Full Description
The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to build a prototype mRNA vaccine containing Mtb-antigens as a safe and effective multivalent therapeutic vaccine against tuberculosis.
Grant Number: 75N93025C00024-0-9999-1
NIH Institute/Center: NIH
Principal Investigator: KAREN ANTHONY
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click